Expanded obesity drug coverage can increase Medicaid spending and put pressure on overall state budgets, and states are now facing tighter budget conditions and longer-term fiscal uncertainty, due in part to the federal Medicaid cuts in the 2025 reconciliation law, causing state Medicaid programs to re-evaluate their obesity drug coverage
It is important to understand that these in vitro models express a different hormonal cocktail and respond to different chemical stimuli than intestinal L-cells in vivo ( The more physiologically relevant studies make use of in vivo transgenic mice, ex vivo perfused intestines or, more recently, crypt organoids derived from human, mouse or porcine guts ( In situ immunostaining and FACS studies have demonstrated that the hormonal secretome of GLP-1-secreting-cells is anatomically dependent
Two format notes
GIPR activation potentiates glucose-dependent insulin release and has more recently been shown to modulate adipose-tissue lipid handling and central appetite pathways
Odczynnik RUO nie jest tirzepatydem w postaci leku, nie jest zamiennikiem Mounjaro ani Zepbound i nie zastpuje konsultacji medycznej
People lost an average of 20.2% of their body weight with tirzepatide compared to 13.7% with semaglutide